JNJ-26854165 (Serdemetan)

Catalog No.S1172

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Cited by 4 Publications

Mol Ther, 2015, 23(5):857-65

PubMed: 25648263 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):40

PubMed: 28577368 ( click the link to review the publication )

Sci Rep, 2014, 4:4664

PubMed: 24722541 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

6 Customer Reviews

Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.
Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.
Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description

Targets

p53 ^[1]
(Cell-free assay)

HDM2 ^[1]
(Cell-free assay)

Mdm2 ^[2]
(Cell-free assay)

In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. ^[1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. ^[2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KU-19-19 cell	M13KVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYrJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46OzJ\|NjFOwG0>	NGLmO4RUSU6JRWK=
H4 cell	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MljsTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwME[3NFch\|ryP	NITTTItUSU6JRWK=
KGN cell	NHLQSppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NV6wR3hLUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYzODVizszN	MkHWV2FPT0WU
786-0 cell	Ml22S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mn[zTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuO\|I6QDlizszN	NVrmO3ljW0GQR1XS
769-P cell	MoG5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH;EXo9KdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OjJ{NDFOwG0>	MVrTRW5ITVJ?
K5 cell	NGXxXlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkDKTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMEG2NlQh\|ryP	MX3TRW5ITVJ?
MLMA cell	NILBRpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYfsNnZyUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB\|MkG3JO69VQ>?	NGPzcmFUSU6JRWK=
MLMA cell	M4rYUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MUDJcohq[mm2aX;uJI9nKGi3bXHuJG1NVUFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkK4O\|A{KM7:TR?=	NWPzbZQ4W0GQR1XS
EW-7 cell	NIX0XWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4S3PWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuN\|I3QTVizszN	MX3TRW5ITVJ?
SW1088 cell	NHvMZmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NV72OZdXUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjhyNkWxJO69VQ>?	NUHjTlVrW0GQR1XS
MC-IXC cell	Mnq5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYLJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFc4QTJizszN	NGjlNFNUSU6JRWK=
NCI-H2052 cell	M2[1Smdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MUDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC1NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODhzNUeg{txO	NUHafJdZW0GQR1XS
IGR-1 cell	MofES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1XxdGlvcGmkaYTpc44hd2ZiaIXtZY4hUUeULUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlEzODJ6IN88US=>	NVyxb3I5W0GQR1XS
DSH1 cell	NFrRZppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYXJcohq[mm2aX;uJI9nKGi3bXHuJGRUUDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkK0Nlk3KM7:TR?=	M1POeXNCVkeHUh?=
PA-1 cell	MnHSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NWLjeWNYUW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{ODB3Od88US=>	NV\QflJvW0GQR1XS
SK-MEL-3 cell	M4\ESGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NG\ncY1KdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5\|MUKwO{DPxE1?	NXfUS2E2W0GQR1XS
SW900 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2DURWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=>	M3jxZ3NCVkeHUh?=
CAKI-1 cell	MoHqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXjJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOVI4OzhizszN	Ml\FV2FPT0WU
ES1 cell	M1nrT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIPr[WxKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOVI5QTdizszN	NGDWRWdUSU6JRWK=
SK-N-DZ cell	NWrkbnZyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYrJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlYzPTl3IN88US=>	MlzHV2FPT0WU
RH-1 cell	Mm\6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M4DnVmlvcGmkaYTpc44hd2ZiaIXtZY4hWkhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOlg1PjNizszN	NGrjU\|VUSU6JRWK=
ES8 cell	MkfKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHjsTYZKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOlk4ODJizszN	MWfTRW5ITVJ?
NEC8 cell	MnPIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|Lke2PVgzKM7:TR?=	NHzVdG1USU6JRWK=
LNCaP-Clone-FGC cell	M3XFZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWDJcohq[mm2aX;uJI9nKGi3bXHuJGxPS2GSLVPsc45mNU[JQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFM2OzZizszN	M{PBV3NCVkeHUh?=
HCE-4 cell	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYLiUoRyUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0>	NEfu[G1USU6JRWK=
U-118-MG cell	Mm\LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NY\FR296UW6qaXLpeIlwdiCxZjDoeY1idiCXLUGxPE1OTyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwMEGwOlYh\|ryP	NIDl[GVUSU6JRWK=
GI-ME-N cell	Mlz1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NX;SNII3UW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yOEe5OkDPxE1?	NXm0WmVTW0GQR1XS
LB1047-RCC cell	M4jSbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYf0SZFVUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xOlE1OyEQvF2=	NXvQVG9DW0GQR1XS
HT-1080 cell	M1nVSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFzNXFdKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF7OUKxJO69VQ>?	MnfSV2FPT0WU
NB69 cell	M1z4T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NITSOJNKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM2ODR5IN88US=>	M2\wT3NCVkeHUh?=
NCI-H1693 cell	NV7QVVRzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUDxTY5IUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3QTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkS0PFk2KM7:TR?=	NWrWXGI5W0GQR1XS
HSC-3 cell	NWnpdHAyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND60PVk{OyEQvF2=	MV7TRW5ITVJ?
MDA-MB-231 cell	NEDv[2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2XKT2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwNUW4PVkh\|ryP	NVnOTY9qW0GQR1XS
HOS cell	NFXVW4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwN{i2N{DPxE1?	M4nNTnNCVkeHUh?=
BT-549 cell	M{PZb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWrJcohq[mm2aX;uJI9nKGi3bXHuJGJVNTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuO\|g5PyEQvF2=	MYPTRW5ITVJ?
NB17 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnThTY5pcWKrdHnvckBw\iCqdX3hckBPSjF5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND63PFk4PiEQvF2=	Mnv3V2FPT0WU
5637 cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUK3[ZA6UW6qaXLpeIlwdiCxZjDoeY1idiB3NkO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QTZ3MjFOwG0>	MYrTRW5ITVJ?
OVCAR-8 cell	NV;4bmNYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mnf0TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OjR\|NjFOwG0>	NEjMXJVUSU6JRWK=
G-402 cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M133dWlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk{ODN3IN88US=>	MVHTRW5ITVJ?
BB30-HNC cell	M{\hPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmXGTY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODd{MUig{txO	MmnpV2FPT0WU
HCC1806 cell	NF3UfHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MljCTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzOEC2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xQDN\|OTFOwG0>	NWm2VXpJW0GQR1XS
COLO-800 cell	M{DvN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MkLrTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTJ4NDFOwG0>	NWmxeHU4W0GQR1XS
FADU cell	M4S1Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{i3dGlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|Y2PTdizszN	MV3TRW5ITVJ?
NCI-H1651 cell	NY[zcVcxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXT5fHFYUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkO5OFA6KM7:TR?=	M2iyb3NCVkeHUh?=
AGS cell	NFPicmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlvYTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3O\|EyKM7:TR?=	NWPud4ZsW0GQR1XS
CHP-212 cell	M1rZS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUnDeHBQUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5\|OUSwPUDPxE1?	MkTKV2FPT0WU
YAPC cell	M3;ofmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYPJcohq[mm2aX;uJI9nKGi3bXHuJHlCWENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3O\|EyKM7:TR?=	MojWV2FPT0WU
GOTO cell	MlzMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3nzOGlvcGmkaYTpc44hd2ZiaIXtZY4hT0:WTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOFk2PzZizszN	MWrTRW5ITVJ?
KYSE-510 cell	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mn3KTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTFzIN88US=>	NUXDZ2YxW0GQR1XS
NCI-H2342 cell	M4DuT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3rINGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN\|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{K3PEDPxE1?	MnfmV2FPT0WU
BFTC-905 cell	MofrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVPJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh\|NTFOwG0>	NUTDS2s5W0GQR1XS
EW-16 cell	NHSwUnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUnuXG8xUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzJyOUOg{txO	MWrTRW5ITVJ?
SK-MEL-30 cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzR3NEOg{txO	Ml;LV2FPT0WU
HLE cell	NYSxdIRXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXW2RYFoUW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc4PDh7IN88US=>	NFvxdXNUSU6JRWK=
T98G cell	MmfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXvJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5OlM2KM7:TR?=	M13leHNCVkeHUh?=
HUTU-80 cell	M17PPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg1OjJ6IN88US=>	MUnTRW5ITVJ?
NOS-1 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT65OFc3PiEQvF2=	NVTxOlNVW0GQR1XS
SW780 cell	NYDTOY41T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYHJNW13UW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTZ7NEmg{txO	MmfqV2FPT0WU
KYSE-180 cell	MoHVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHTIVJZKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57N{[1OEDPxE1?	NVTMRohJW0GQR1XS
MDA-MB-361 cell	M4XRUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M331d2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVM3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUi2OFch\|ryP	MV;TRW5ITVJ?
SNU-C2B cell	NWDXT5RlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlLBTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvQ{LCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xOTF\|ODFOwG0>	NUL3dIxWW0GQR1XS
NCI-H661 cell	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NV[2bJdEUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwME[5OEDPxE1?	NUG2W\|FWW0GQR1XS
OE33 cell	MlPMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M4nrT2lvcGmkaYTpc44hd2ZiaIXtZY4hV0V\|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNVQ{QDlizszN	MnnTV2FPT0WU
TYK-nu cell	NGDZWHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Ml32TY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIyQDZ\|IN88US=>	NIXrUnZUSU6JRWK=
COLO-792 cell	NGjFXGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPTJzOTFOwG0>	NX7IfppLW0GQR1XS
HEL cell	NIe4O2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwMk[3OkDPxE1?	MUPTRW5ITVJ?
D-566MG cell	NUXaN\|lJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnvwTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{OzR7MTFOwG0>	NF3HUpZUSU6JRWK=
U031 cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NIH0N\|NKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQyQDF4IN88US=>	MXTTRW5ITVJ?
COR-L23 cell	M4fHbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MojSTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzN2NjFOwG0>	NIPjVIhUSU6JRWK=
NCI-H2452 cell	MlPsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFrtd4dKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlQ2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwNUKyPFEh\|ryP	NGDhb4tUSU6JRWK=
BB65-RCC cell	MoS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmT4TY5pcWKrdHnvckBw\iCqdX3hckBDSjZ3LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjR3OTFOwG0>	MnP5V2FPT0WU
CAL-33 cell	NXHZS2tJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUWxT4ZYUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ3Nk[1JO69VQ>?	NFj3fY1USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells Concentrations: 0-10 μM Incubation Time: 72 hours Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK (Only for Reference)
Animal Research:^[4]	+ Expand Animal Models: CB17SC scid^-/- female mice. Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water. Dosages: ≤20 mg/kg Administration: Administered via p.o. (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
Concentrations: 0-10 μM
Incubation Time: 72 hours
Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
(Only for Reference)

Animal Research:^[4]

+ Expand

Animal Models: CB17SC scid^-/- female mice.
Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
Dosages: ≤20 mg/kg
Administration: Administered via p.o.
(Only for Reference)

References

[4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

+ Expand

Solubility (25°C)

In vitro	DMSO	66 mg/mL (200.96 mM)
	Ethanol	2 mg/mL (6.08 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Molecular Weight	328.41
Formula	C₂₁H₂₀N₄
CAS No.	881202-45-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00676910	Completed	Neoplasms	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	November 2006	Phase 1
NCT00676910	Completed	Neoplasms	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	November 2006	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p53 Signaling Pathway Map

Related p53 Products0

MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
RITA (NSC 652287)

RITA (NSC 652287) induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.

Features:Inducer of DNA cross-links, not a DNA intercalator.
Pifithrin-α (PFTα) HBr

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.
Tenovin-1

Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2.
Tenovin-6

Tenovin-6 is a small molecule activator of p53 transcriptional activity.
NSC 319726

NSC319726 is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibition for p53 wild-type cells.

Features:An allele-specific p53 mutant reactivator.
Pifithrin-μ

Pifithrin-μ is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.
Z-VAD-FMK

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Features:A key compound for apoptosis studies.

Choose Your Country or Region

By Signaling Pathways

By product type

JNJ-26854165 (Serdemetan)

Cited by 4 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

p53 Signaling Pathway Map

Related p53 Products0

Choose Your Country or Region

By Signaling Pathways

By product type

JNJ-26854165 (Serdemetan)

Cited by 4 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

p53 Signaling Pathway Map

Related p53 Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)